The prevention and treatment of hypertension is a public health challenge, in part because most patients treated for hypertension do not achieve adequate blood pressure (BP) control. Noncompliance is a common cause, influenced by factors such as tolerability, tablet load, complexity, efficacy, and cost. Additionally, patients may question the need for lifetime treatment of an asymptomatic condition with medications that often reduce their quality of life. Clinical inertia, underdosing, and limited use of combination and new treatments also contribute. Strategies to improve BP control include the use of highly effective, long-acting, and well-tolerated antihypertensives that encourage adherence, with efficacy that extends beyond the 24-hour dosing period to provide lasting protection and mitigation against the effects of missed doses. Angiotensin receptor blockers (ARBs) encourage higher adherence than other antihypertensives, and the ARB telmisartan offers 24-hour BP reductions. Ultimately, successful management of hypertension requires the physician to help the patient understand the seriousness of their condition, the implications of noncompliance, and the need for lifetime treatment.
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
Publishing in Gene Regulation and Systems Biology was a very positive experience. I was impressed by the fast and uncomplicated submission process as well as the clear and professional peer review process which helped to improve the manuscript. The Libertas Academica team was very patient and helpful. I would definitely recommend the journal to other colleagues in the field!
All authors are surveyed after their articles are published. Authors are asked to rate their experience in a variety of areas, and their responses help us to monitor our performance. Presented here are their responses in some key areas. No 'poor' or 'very poor' responses were received; these are represented in the 'other' category.See Our Results
Copyright © 2013 Libertas Academica Ltd (except open access articles and accompanying metadata and supplementary files.)